Mepolizumab (Nucala®) 100mg powder for solution for injection

Assessment Status Assessment Process Complete
Drug Mepolizumab
Brand Nucala®
Indication Is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
Assessment Process
Rapid review commissioned 16/03/2016
Rapid review completed 04/04/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 29/07/2016
NCPE assessment completed 01/03/2017
NCPE assessment outcome Reimbursement Not Recommended at the Submitted Price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations May 2018